Veeva Systems (NYSE:VEEV) Given New $325.00 Price Target at Royal Bank Of Canada

Key Points

• Royal Bank of Canada raised Veeva Systems’ price target to $325 from $275 and maintained an “outperform” rating, implying 12.37% upside from the prior close.
• Veeva reported fiscal Q2 revenue of $928 million, up 17.6% year over year, and EPS of $2.35, beating expectations; its quarterly and full-year guidance also exceeded analyst estimates.
• Analyst sentiment remains favorable, with 19 Buy ratings and an overall “Moderate Buy” consensus, though the stock’s elevated valuation and sensitivity to product-adoption execution present risks.

Veeva Systems (NYSE:VEEV - Get Free Report) had its price objective boosted by Royal Bank Of Canada from $275.00 to $325.00 in a research note issued on Thursday,Benzinga reports. The brokerage presently has an "outperform" rating on the technology company's stock. Royal Bank Of Canada's target price would indicate a potential upside of 12.37% from the company's previous close.

Several other research firms have also recently issued reports on VEEV. Citigroup increased their price target on shares of Veeva Systems from $176.00 to $190.00 and gave the stock a "neutral" rating in a report on Thursday, June 4th. Barclays lifted their price objective on Veeva Systems from $235.00 to $275.00 and gave the company an "overweight" rating in a report on Tuesday, August 18th. Guggenheim boosted their target price on Veeva Systems from $276.00 to $310.00 and gave the stock a "buy" rating in a research report on Thursday. BTIG Research reissued a "buy" rating and set a $340.00 target price on shares of Veeva Systems in a research note on Thursday, June 4th. Finally, Jefferies Financial Group reissued a "buy" rating and issued a $295.00 price target on shares of Veeva Systems in a report on Thursday. Nineteen equities research analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $266.08.

Veeva Systems Stock Up 18.1%

Shares of NYSE VEEV traded up $44.31 during mid-day trading on Thursday, hitting $289.22. 1,807,837 shares of the company were exchanged, compared to its average volume of 2,445,541. The stock has a 50 day simple moving average of $203.41 and a 200-day simple moving average of $183.04. Veeva Systems has a 1-year low of $148.05 and a 1-year high of $310.50. The firm has a market cap of $46.98 billion, a price-to-earnings ratio of 51.73, a price-to-earnings-growth ratio of 1.06 and a beta of 0.92.

Veeva Systems (NYSE:VEEV - Get Free Report) last announced its quarterly earnings data on Wednesday, August 26th. The technology company reported $2.35 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.22 by $0.13. Veeva Systems had a net margin of 28.37% and a return on equity of 13.72%. The company had revenue of $927.96 million for the quarter, compared to analysts' expectations of $905.38 million. During the same period in the previous year, the company posted $1.99 EPS. Veeva Systems's revenue was up 17.6% compared to the same quarter last year. Veeva Systems has set its FY 2027 guidance at 9.210-9.210 EPS and its Q3 2027 guidance at 2.330-2.340 EPS. Analysts anticipate that Veeva Systems will post 6.65 earnings per share for the current fiscal year.

Insider Transactions at Veeva Systems

In other news, insider Thomas D. Schwenger sold 36,000 shares of Veeva Systems stock in a transaction that occurred on Thursday, August 13th. The shares were sold at an average price of $250.23, for a total transaction of $9,008,280.00. Following the completion of the sale, the insider directly owned 19,449 shares in the company, valued at approximately $4,866,723.27. This trade represents a 64.92% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 10.60% of the company's stock.

Hedge Funds Weigh In On Veeva Systems

Several hedge funds have recently bought and sold shares of the company. California State Teachers Retirement System grew its holdings in Veeva Systems by 16,590.3% in the second quarter. California State Teachers Retirement System now owns 39,388,224 shares of the technology company's stock valued at $6,990,228,000 after purchasing an additional 39,152,230 shares during the last quarter. Principal Financial Group Inc. raised its stake in shares of Veeva Systems by 7.0% during the 1st quarter. Principal Financial Group Inc. now owns 4,141,545 shares of the technology company's stock worth $727,513,000 after buying an additional 271,252 shares during the last quarter. State Street Corp raised its stake in shares of Veeva Systems by 2.4% during the 4th quarter. State Street Corp now owns 3,589,425 shares of the technology company's stock worth $801,267,000 after buying an additional 85,695 shares during the last quarter. Geode Capital Management LLC boosted its position in shares of Veeva Systems by 0.7% in the 4th quarter. Geode Capital Management LLC now owns 3,172,716 shares of the technology company's stock worth $706,442,000 after buying an additional 23,117 shares in the last quarter. Finally, AQR Capital Management LLC boosted its position in shares of Veeva Systems by 31.2% in the 3rd quarter. AQR Capital Management LLC now owns 2,412,210 shares of the technology company's stock worth $706,078,000 after buying an additional 574,164 shares in the last quarter. 88.20% of the stock is owned by hedge funds and other institutional investors.

Veeva Systems News Roundup

Here are the key news stories impacting Veeva Systems this week:

• Positive Sentiment: Veeva reported fiscal Q2 revenue of $928.0 million, up 17.6% year over year, while EPS of $2.35 exceeded the $2.22 analyst consensus. Subscription revenue increased 16% to $766.8 million. Veeva Announces Fiscal 2027 Second Quarter Results
• Positive Sentiment: Management issued fiscal Q3 revenue guidance of approximately $932 million-$935 million and EPS guidance of $2.33-$2.34, both above Wall Street expectations. Full-year fiscal 2027 EPS guidance of $9.21 and revenue guidance of about $3.7 billion also exceeded consensus estimates. Veeva Q2 2027 Earnings Call Transcript
• Positive Sentiment: Executives highlighted continued strength in Vault CRM, targeting more than 70% market share, and said the first Falcon customer deployments are expected this year. AI-related capabilities are also contributing to demand and revenue growth. Veeva CRM and Falcon Update
• Positive Sentiment: Needham reaffirmed its Buy rating, while Piper Sandler initiated coverage, adding favorable analyst attention following the earnings release. Needham Reaffirms Buy Rating
• Neutral Sentiment: Analyst commentary emphasized Veeva’s combination of recurring growth, strong margins and financial strength, but the stock’s elevated valuation—around 44 times earnings—leaves less room for execution or guidance disappointments.
• Negative Sentiment: The modest decline in the shares despite the earnings and guidance beats suggests investors may be taking profits or were already pricing in strong results. Near-term sentiment could remain sensitive to valuation and the pace of new product adoption.

Veeva Systems Company Profile

Veeva Systems NYSE: VEEV is a cloud software company that develops industry-specific applications and data solutions for the global life sciences sector. Founded in 2007 and headquartered in Pleasanton, California, Veeva focuses on helping pharmaceutical, biotechnology, medical device and consumer health companies manage regulated content, clinical and regulatory processes, quality systems, and commercial operations in a compliant, cloud-native environment. The company completed its initial public offering in 2013 and has since expanded its product suite and international footprint.

Veeva's product portfolio centers on its Vault platform and related application suites, which provide content and data management, clinical trial and regulatory workflows, quality management, and structured commercial capabilities such as customer relationship management and promotional content management.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source